Navigation Links
Glaucoma Survey: Half Unaware of Preservative-Free Beta-Blocker, Ophthalmologists Cite Benefits of Preservative-Free Medications on Ocular Comfort and Quality of Life
Date:4/6/2009

o preservatives at all for their glaucoma patients with ocular surface disease or dry eye syndrome, compared to glaucoma medications preserved with BAK (3%) or non-BAK preservatives (36%).

Preservative-Free Beta-blocker

Nearly half (47%) do not know a preservative-free beta-blockers is available. TIMOPTIC(R) (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) is the only preservative-free medication for glaucoma available in the U.S. The TIMOPTIC product line was recently acquired by Aton Pharma, Inc., which provides the dry eye medication LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, patient-administered prescription insert indicated for moderate to severe dry eye.

"A preservative-free beta blocker is a consideration for many glaucoma patients, especially for those who already have dry eye or are at increased risk for ocular surface disease, such as the elderly, those on oral medications associated with dry eye and patients with existing lid margin disease," continued Dr. Trattler. "The use of a preservative-free glaucoma medication such as TIMOPTIC in OCUDOSE can help preserve the health of the ocular surface in glaucoma patients."

Survey Methodology

The survey, sponsored by Aton Pharma, was completed between March 24 and March 26, 2009. Ophthalmologists across the nation were invited via e-mail to enter the online survey, and those who treated 20 or more glaucoma patients per month were asked to complete the survey. A total of 124 completed the survey, including 36 glaucoma specialists and 40 cataract surgery specialists.

About TIMOPTIC(R) in OCUDOSE(R)

TIMOPTIC(R) (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) is a preservative-free, non-selective beta-adrenergic receptor blocking agent ind
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Glaucoma surgery in the blink of an eye
3. Glaucoma surgery in the blink of an eye
4. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
5. Looking at Glaucoma as a Systemic Disease
6. Cost of glaucoma medications may impact treatment
7. January is National Glaucoma Awareness Month
8. Upcoming meeting will explore new technologies for glaucoma clinical drug trials
9. Dr. Welsh Self-Test Diagnoses Glaucoma, the Leading Cause of Preventable- Blindness
10. Mayor Bloomberg Declares March 6, 2008 World Glaucoma Day in New York City
11. Glaucoma May Boost Cardiovascular Death Risk in Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... a recent study that came out in the journal Environmental ... plastics on human beings. ,Bisphenol-A (BPA) is a ... grade materials for making air tight containers, drinking water bottles, ... of Medicine did the study to find out about the ...
... that spreads through mosquito bites, among other things, did not ... of Nature Medicine scientists have shown a successful treatment on ... developed an antibody that can successfully fight the virus. The ... naturally against this virus and in turn never get affected ...
... study made by researchers of UK, scientists have found that ... the blood of the passengers. ,The study was done ... today, do have any effect on the health of the ... peripheral oxygen saturation and pulse rate of 84 passengers, aged ...
... cure people suffering from hay fever by teaching them self-hypnosis.//,The ... curing allergic reactions. 79 patients of an average age of ... or pollen were taken in the study. All these people ... years. Random parallel group was used as control for the ...
... to be a risk factor for multiple sclerosis. New ... more in people suffering from multiple sclerosis. ,In ... of medicine, researchers had been able to associate habitual ... sclerosis. In a study comprising of 201 cases of ...
... addiction is a problem because the addicts find it hard ... this type of behavior may be that drugs affect the ... towards other rewards of life, like eating and fulfilling of ... treat drug addiction may be a surgical procedure by which ...
Cached Medicine News:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... N.J. and MORRISTOWN, N.J., June 27, 2011 Columbia Laboratories, ... (NYSE: WPI ) today announced that the U.S. ... New Drug Application (NDA) for PROCHIEVE ® (progesterone gel) ... with short uterine cervical length in the mid-trimester of pregnancy. ...
... International (CDI) today announced the online publication of an ... the first time a methodology for researchers to access ... through the creation of induced pluripotent stem cells (iPSCs). ... reprogrammed to EBV-free induced pluripotent stem cells," the derived ...
Cached Medicine Technology:Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 2Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 3Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 4Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
Cold light source triple outlet....
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Head-worn Loupe KF Titanium the teleloupe system is mounted on a special frame with straight temples and an elastic headband....
Medicine Products: